On March 8, 2022 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, reported that the Company will present a poster and three oral presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place between April 8-13, 2022 in New Orleans, Louisiana and virtually (Press release, C4 Therapeutics, MAR 8, 2022, View Source [SID1234609972]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations at AACR (Free AACR Whitepaper) Annual Meeting 2022:
Title: CFT7455: Pharmacokinetic (PK) Profile of a Novel IKZF1/3 Degrader, CFT7455, Enables Significant Potency Advantage over Other IKZF1/3 Degraders in Models of Multiple Myeloma (MM) and the Results of the Initial Treatment Cohort from a First-in-Human (FIH) Phase 1/2 Study of CFT7455 in MM
Abstract Number: CT186, Poster
Time: Tuesday, April 12, 2022, 9:00 AM – 12:30 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 33
Presenter: Sagar Lonial, M.D., FACP, chief medical officer, Winship Cancer Institute of Emory University; professor and chair, department of hematology and medical oncology, Emory University School of Medicine
Title: The discovery and characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma
Abstract Number: 7922, Oral
Time: Monday, April 11, 2022, 10:15 AM -11:45 AM CT
Location: New Orleans Convention Center, La Nouvelle Orleans A-B
Session: New Drugs on the Horizon: Part 3
Presenter: Jim Henderson, Ph.D., vice president of chemistry, C4 Therapeutics
Title: The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers
Abstract Number: 7756, Oral
Time: Sunday, April 10, 2022, 3:00 PM – 4:30 PM CT
Location: New Orleans Convention Center, La Nouvelle Orleans A-B
Session: New Drugs on the Horizon: Part 2
Presenter: Kate Jackson, Ph.D., senior director of chemistry, C4 Therapeutics
Title: Preclinical Evaluation of CFT1946 as a Selective Degrader of Mutant BRAF for the Treatment of BRAF Driven Cancers
Abstract Number: 2158, Oral
Time: Monday, April 11 2:30 PM – 4:30 PM CT
Location: New Orleans Convention Center, Great Hall AD
Session: Emerging New Anticancer Agents
Presenter: Mathew Sowa, Ph.D., senior director, proteomics and ubiquitin proteasome system biology, C4 Therapeutics
In addition to these data presentations, Chris Nasveschuk, senior vice president, chemistry, will be participating in the Targeted Protein Degradation: Access to New Medicines by Drugging Challenging Targets educational session on Friday, April 8, 2022 from 5:30 PM to 5:50 PM CT.
Investor Webcast Information
C4T will host an investor webcast on Friday, April 8, 2022 at 2 PM ET to discuss the CFT7455 Cohort A clinical data that will be presented at the AACR (Free AACR Whitepaper) Annual Meeting. The webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be available on C4T’s website for 30 days following the event.